ProQR Therapeutics N.V. Logo

ProQR Therapeutics N.V.

Biotech developing RNA-editing therapies for genetic disorders using the body's own enzymes.

PRQR | US

Overview

Corporate Details

ISIN(s):
NL0010872495
LEI:
Country:
United States of America
Address:
ZERNIKEDREEF 9, LEIDEN
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ProQR Therapeutics N.V. is a biotechnology company dedicated to the discovery and development of RNA therapies for severe rare and common genetic disorders. The company's core focus is its proprietary Axiomer® RNA-editing technology platform. This platform is designed to make targeted edits to RNA by recruiting the body's own ADAR (Adenosine Deaminase Acting on RNA) enzymes, representing a novel approach to treating diseases with high unmet medical needs. ProQR advances its technology through in-house research and development as well as strategic partnerships, including a major collaboration with Eli Lilly and Company to discover, develop, and commercialize new medicines.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ProQR Therapeutics N.V. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ProQR Therapeutics N.V.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ProQR Therapeutics N.V. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Eledon Pharmaceuticals, Inc. Logo
Develops immunomodulatory therapies to prevent organ rejection in transplant patients.
United States of America ELDN
Elicera Therapeutics AB Logo
Develops CAR T-cell & oncolytic virus therapies for cancer, enhanced by its iTANK platform.
Sweden ELIC
ELI LILLY & Co Logo
Pharma leader developing medicines for diabetes, obesity, oncology, and neuroscience.
United States of America LLY
Ellen AB Logo
Develops research-based probiotic and prebiotic products for women's intimate health and pH balance.
Sweden ELN
ELUTIA INC. Logo
Develops drug-eluting biologics to reduce complications from medical implants.
United States of America ELUT
Emergent BioSolutions Inc. Logo
Develops and manufactures medical countermeasures for public health and national security threats.
United States of America EBS
ENANTA PHARMACEUTICALS INC Logo
Developing novel small molecule drugs for virology (HCV, RSV) and immunological diseases.
United States of America ENTA
enGene Holdings Inc. Logo
Developing non-viral, locally administered gene therapies for rare genetic conditions.
United States of America ENGN
Enliven Therapeutics, Inc. Logo
A clinical-stage biopharma developing kinase inhibitors for precision oncology cancer treatment.
United States of America ELVN
Enlivex Therapeutics Ltd. Logo
Developing cell therapy that reprograms macrophages to treat immune hyper-responses like sepsis.
United States of America ENLV

Talk to a Data Expert

Have a question? We'll get back to you promptly.